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Objectives: To estimate the frequency and determine
the risk factors for incident dementia in community-
dwelling patients with Parkinson's disease (PD) and in
control subjects.
Design: Prospective cohort study. During a 3.5-year pe-
riod, 140 patients with idiopathic PD without evidence of
dementia and 572 nondemented control subjects were iden-
tified in the community of Washington Heights\p=m-\Inwood
in New York, NY. All subjects underwent neurological and
neuropsychological evaluations and follow-up examinations.
Results: Twenty-seven patients with PD (19.2%) became
demented throughout 2 years, as compared with 87(15.2%)
of the control subjects. The relative risk (RR) for the devel-
opment of dementia with PD was 1.7 (95% confidence in-
terval [CI], 1.1 to 2.7) after adjusting for age, education,
and gender. Predictive features of incident dementia were
an extrapyramidal score greater than 25 (RR, 3.56; 95% CI,
1.4 to 8.9) and a Hamilton Depression Rating Scale score
greater than 10 (RR, 3.55; 95% CI, 1.6 to 7.9).
Conclusion: Patients with PD, especially those with se-
vere extrapyramidal signs, have almost twice the risk for
the development of dementia than do community-
dwelling control subjects.
(Arch Neurol. 1995;52:695-701)
Risk factors that are asso¬ciated with dementia in pa¬tients with Parkinson's dis¬ease (PD) include older ageat the onset of motor mani¬
festations, severity of the extrapyramidal
syndrome (particularly bradykinesia), a
family history of dementia, psychologi¬
cal stress (eg, Holocaust), depression, hy¬
pertension, and low socioeconomic or low
educational attainment.1"3 Most studies of
risk factors for dementia in patients with
PD have been retrospective, although four
longitudinal studies have examined the
predictive value of baseline charac¬
teristics of nondemented patients with
PD.4"7
In our previous cross-sectional stud¬
ies of patients with PD, we hypothesized
that the factors associated with demen¬
tia, ie, age at onset of motor manifesta¬
tions, severity of extrapyramidal signs, and
depressive symptoms, if present at base¬
line examination in nondemented pa¬
tients with PD, would predict the devel¬
opment of dementia.
We examined the risk for the devel¬
opment of dementia in patients with PD as
compared with that in nondemented con¬
trol subjects with no known neurological
disease, which was ascertained in a simi¬
lar manner, from the same community.
RESULTS
Between April 1, 1988 and December 31,
1991, we evaluated 353 patients with pos¬
sible PD. Two hundred seventy-nine pa¬
tients met research criteria for PD.8"10 An
additional 37 patients had essential tremor,
and 37 had other disorders, but not PD.
Of the 279 patients who met re¬
search criteria for PD, 104 (37.3%) were
demented at their first evaluation and were
not included in the analysis.
Of 175 nondemented patients with
PD, 35 were seen only once and were not
included in the proportional hazards analy¬
sis. Fourteen of the 35 patients, who were
seen only once, died within the year prior
to their first follow-up; 12 were not yet due
for their follow-up; and nine could not be
found despite repeated attempts to con¬
tact them.
See Methods on next page
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METHODS
SUBJECTS AND SETTING
All patients with PD and control subjects were participants
in a study ofdegenerative disease in elderly persons who were
living in the Washington Heights-Inwood section ofnorth¬
ern Manhattan (New York, NY). A registry of cases for sev¬
eral diseases, including PD, was developed from a number
ofsources: regional hospitals (including inpatient and out¬
patient services), private practitioners in the community,
health maintenance organizations, senior citizens centers,
federal and state health agencies, and newspaper and radio
announcements. Neurology clinic records at Harlem Hos¬
pital, New York, NY, were reviewed for cases of PD, and two
neurologists at the Allen Pavilion, a satellite hospital at the
tip ofManhattan, referred all cases of PD to the registry. Rec¬
ords of patients at the regional Health Insurance Providers
of New York (NY) were screened for PD. In addition, the
Health Resources Association, New York, allowed us to re¬
view all patients' records in the area who had home health
aides.
CRITERIA FOR IDIOPATHIC PD
Idiopathic PD was defined by clinical and research crite¬
ria.8"10 We excluded patients with secondary or symptom¬
atic parkinsonism, ie, parkinsonism that resulted from
treatment with phenothiazines, methyldopa (alpha-
methyldopa), reserpine, or metoclopramide hydrochlo¬
ride. Patients with clinical presentations that were sugges¬
tive of progressive supranuclear palsy, essential tremor, Shy-
Drager syndrome, presumed striatonigral degeneration, and
olivopontocerebellar atrophy were excluded. Patients who
by history from an informant experienced cognitive im¬
pairment that was sufficient to meet criteria for dementia
prior to the development of the motor manifestations of
PD without any atypical features were considered in the
majority of cases to have the "extrapyramidal form" of Alz¬
heimer's disease.11 They were excluded in an effort to in¬
clude only patients with idiopathic PD who were nonde¬
mented at their baseline visit.
CRITERIA FOR CONTROL SUBJECTS
Control subjects were volunteers who were living in the
same geographical area in northern Manhattan. Control sub¬
jects were also referred by community-based health pro¬
viders, and they were recruited from senior citizens cen¬
ters and housing, nursing homes that were serving local
residents, and a state agency list of home care recipients.
Requirements included (1) being nondemented at base¬
line examination based on the neuropsychological para¬
digm and (2) having no evidence of any neurodegenera-
tive disease, such as PD or stroke. Depression was not an
exclusion in the group of control subjects. All control sub¬jects were seen by a neurologist and were older than 60 years
when they were recruited.
NEUROLOGICAL ASSESSMENT
Extrapyramidal signs were rated by using the Unified Par¬
kinson's Disease Rating Scale (UPDRS).12 Reliability of the
assessment of extrapyramidal signs by the three raters (K.M.,
L.C., and R.M.) for the presence of resting tremor, rigidity,
rapid-alternating movements, bradykinesia, and gait was pre¬
viously demonstrated to be excellent in patients with PD.13
An extrapyramidal sign score was calculated by sum¬
ming the scores on the individual items that were rated on
the motor portion of the UPDRS. All items were rated from
a score of 0 to 4, with 0 being normal and 4 indicating se¬
vere impairment. Individual limbs, the face, and the neck
were assessed separately for tremor at rest and rigidity. Ac¬
tion tremor was rated only in the arms. Other items that
were included were speech, facial expression, opening/
closing the hands, pronation/supination of the hands, leg
agility, arising from a chair, posture, postural stability, gait,
and bradykinesia.
A shortened version of the UPDRS was used to rate
extrapyramidal signs in control subjects. Assessment of rest¬
ing tremor, rigidity, speech, facial expression, posture, and
bradykinesia was done by using the items from the UPDRS.
NEUROPSYCHOLOGICAL TEST BATTERY
Subjects were considered demented if they met the re¬
search criteria established for the diagnosis in this popu¬
lation, based on the criteria according to the Diagnostic and
Statistical Manual of Mental Disorders, Revised Third Edi¬
tion (DSM-ÍÍÍ-R),14 and if they or an informant reported func¬
tional difficulties that could be attributed to cognitive rather
than physical disability. The neuropsychological battery was
used to operationalize the DSM-ÍJÍ-R criteria for cognitive
impairment. Details of the paradigm have been reported
previously.15
OTHER ASSESSMENTS
Demographical information that was collected included age
and education. Duration of PD was calculated based on ei¬
ther the patient's age or the date at which motor signs be¬
gan (age at onset of PD) until the baseline examination.
AÍ1 subjects were asked about current medication use
The 35 patients who underwent only a baseline ex¬
amination and were not included in the Cox propor¬
tional hazards model were significantly older (age, 74.1
years) (P=.05) than were the 140 patients who were fol¬
lowed up (age, 71.1 years) but were not significantly dif¬
ferent in age at onset of PD, duration of PD, gender, edu¬
cation, mean EPS, or mean HDRS score. A significantly
higher proportion of those with only a baseline visit(35.5%) as compared with those who were followed
up (19.1%) had HDRS scores of 11 or higher. During
the study period, 40% of those with only a baseline visit
died, as compared with 11.4% of those who were fol¬
lowed up.
An additional 40 patients had only 1 year of follow-
up. At the 1-year follow-up visit, 29 remained nonde¬
mented and 11 had become demented. Six of the 40 pa¬
tients died prior to their 2-year visit, 30 were not yet due
for their second annual visit, and four were unavailable
for follow-up.
One hundred patients had a 2-year follow-up
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and medical history, including cardiovascular disease (eg,
stroke) and head injury with loss of consciousness. Use of
dopamine agonists, anticholinergics, antidepressants, and
anxiolytics was recorded, but response to medication and
dose were not systematically noted. Informants were able
to corroborate historical data. Signs on neurological ex¬
amination, even in the absence of a known history of stroke
or computed tomographic or magnetic resonance imaging
evidence of stroke, were considered indicative of stroke.
To assess activities ofdaily living, we used the Activities
of Daily Living (ADL) Scale of Schwab and England.16 If an
informant was available, information from both the patient
and the informant was used to rate the patient's condition.
Depressive symptoms were rated by using the stan¬
dardized semistructured interview for the Hamilton De¬
pression Rating Scale (HDRS).17 This scale was not used
to make a DSM-/ÍÍ-R diagnosis of major depression, but
rather to enumerate depressive symptoms. A total score was
calculated by summing the scores on the 17 individual items.
DATA ANALYSIS
Patients With PD
To determine the baseline characteristics associated
with the development of dementia, patients with PD were
divided into two groups based on their dementia status af¬
ter a maximum of 2 years of follow-up. Patients and con¬
trol subjects who were seen only once were not included
in the analysis.
The subjects who remained nondemented during their
observation period were compared with those who had a
new onset of dementia on many clinical variables that were
related to the study hypothesis. These variables were col¬
lected at their baseline visit and were compared by using
 2 tests or t tests. Those variables with a significance level
of <. 10 were included in a Cox proportional hazards model
to predict incident dementia. Median values were substi¬
tuted for continuous variables, with the exception of the
HDRS; the HDRS scores were evaluated in three separate
ways. The median HDRS score was used in the Cox model;
however, because the median score of 5 was too low to be
representative of either dysthymia or major depression, we
also chose an HDRS score of greater than 10, which we be¬
lieved was representative of significant depressive symp¬
toms—although not indicative of meeting DSM-JÍ/-R cri¬
teria for major depression. In a longitudinal study of patients
with PD, Starkstein et al6 found that patients who met DSM-
JII-R criteria for major depression had a mean HDRS score
of 15.4 (SD, 3.4), while patients who met criteria for dys¬
thymia had a mean HDRS score of 8.4 (SD, 2.3) and those
with no depression had a mean HDRS score of 2.2 (SD, 1.6).
In a sample of 36 patients from our registry in the Wash¬
ington Heights-Inwood community that included 13 pa¬
tients with PD, who were evaluated with both the HDRS
and the Structured Clinical Interview for DSM-UI-R, an
HDRS score greater than or equal to 10 had 50% sensitiv¬
ity and 83% specificity for a DSM-ÍIÍ-R diagnosis of major
depression but only a 38% positive predictive value. The
negative predictive value of an HDRS score of 10 or greater
was 89%. In the sample of 36 patients, the most sensitive
predictor of major depression was the mood item of the
HDRS (83%), even when it was dichotomized as absent(score, 0) or 1 or greater. Therefore, we also included the
mood item in the Cox model; this mood item was dichoto¬
mized as present or absent to predict incident dementia.
An ADL Scale score of 70%, which represented the me¬
dian score, indicated the first level at which a subject was not
completely independent. In this sample, the ADL Scale scores
were highly correlated with those ofboth the Barthel Index18
and the Blessed Functional Activity Scale (Part I).19
Data from those patients with fewer than 2 years of
follow-up—either because of recent study entry or unavail¬
ability for follow-up, were censored. Study end points were
either the development of dementia, death, or being alive
and nondemented at the end of 2 years of follow-up.
Determination of the Relative Risk (RR)
of Dementia in PD
The incidence ofdementia among nondemented patients with
PD was compared with the incidence ofdementia among con¬
trol subjects throughout the follow-up period. Cox propor¬
tional hazard models were used to calculate the RR of de¬
mentia, when data from nondemented patients with PD and
control subjects were compared. The  2 tests or t tests were
used to compare the demographical characteristics of the
group ofpatients with PD and the group of control subjects,
and appropriate covariates were included in the model.
In a separate analysis, using only the items on the
UPDRS that were common to both the evaluations of pa¬
tients with PD and the control subjects, the patients with PD
were split into two groups (those with high extrapyramidal
scores [EPSs] and those with low EPSs) based on the median
extrapyramidal sign score. Control subjects were divided
solely on the basis of the presence or absence of
extrapyramidal signs because EPSs were so infrequent and
mild in the group of control subjects. None of the control
subjects met research criteria for PD.8"10 The control sub¬jects without extrapyramidal signs were considered a refer¬
ence group, and the three other groups (those with PD with
a high EPS, those with PD with a low EPS, and control sub¬
jects with extrapyramidal signs) were included in a Cox
model, adjusting for age, education, and gender.
ease duration, gender, and education did not differ
among those who remained nondemented and those
with incident dementia.
Thirty-nine of the 140 patients who were not de¬
mented at baseline had cognitive impairment that was
insufficient to meet criteria for dementia. Sixteen of these
39 patients were among the 27 patients who eventually
became demented.
The frequency of head injury and stroke did not sig¬
nificantly differ in those patients who did and did not
visit, at which time 84 were nondemented and 16 were
demented. A total of 27 patients became demented
during the 2-year period, resulting in an incidence rate
of 112.5/1000 person-years of observation in this
cohort.
Baseline characteristics of the 140 patients who
were included in the Cox model are presented in
Table I. Patients who did not become demented were
significantly younger at the time that their motor signs
of PD began than those with incident dementia. Dis-
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are given as means (SDs). Analysis was performed with t or  2 tests.
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*RR indicates relative risk; CI, confidence interval; EPS, extrapyramidal
score; and HDRS, Hamilton Depression Rating Scale.
Table 3. Cumulative Incidence of Dementia
Among Patients With PD*
Cumulative Incidence
of Dementia by Age, y
Baseline EPS
=25 >25
*PD indicates Parkinson's disease; EPS, extrapyramidal score.
become demented. Seventy-six percent of the 140 pa¬
tients were receiving at least one medication for the treat¬
ment of PD at their baseline evaluation, when all were
nondemented. The percentage of patients who were re¬
ceiving levodopa (nondemented, 62.8%; demented, 63%),
anticholinergics (nondemented, 14.2%; demented,
18.5%), and dopamine agonists (nondemented, 28.3%;
demented, 29.6%) did not differ at the baseline exami¬
nation between those who remained nondemented and
those who became demented.
All 140 nondemented patients were forward loaded
into the Cox proportional hazards model. The follow¬
ing covariates were entered into the Cox proportional haz¬
ards model: gender, education, median EPS, median ADL
Scale score, and an HDRS score greater than 10. Strati¬
fication of the entire group by age at the time of baseline
evaluation (>72 or ^72 years) was performed. The RRs
of dementia associated with these risk factors are shown
in Table 2.
An EPS greater than 25 and an HDRS score greater
than 10 were independently and significantly associ¬
ated with dementia in this cohort. Education, gender, ADL
Scale score, and age at onset did not contribute signifi¬
cantly to the model.
Cumulative incidence of dementia increased with
advancing age in patients with severe EPSs (Table 3).
The cumulative incidence of dementia by the age of 90
years in patients with a baseline total EPS greater than
25 was 48%, as compared with 14% in those with a
total EPS less than or equal to 25 (Tables 2 and 3).
The cumulative incidence of dementia by the age of 90
years in patients with a baseline HDRS score greater
than 10 was 64%, as compared with 29% in those with
an HDRS score less than or equal to 10 (Table 2).
DEPRESSION
Depression was also evaluated by substituting the me¬
dian HDRS score of 5 instead of an HDRS score greater
than 10 in the Cox model. An EPS greater than 25 re¬
mained significant (RR, 3.4), but depression, measured
by the median HDRS score, was not (P<.09). When the
presence or absence of depressed mood was substituted
for the median HDRS score in the Cox model with the
identical covariates, it too was not an independent pre¬
dictor of dementia, although it approached statistical sig¬
nificance (P<.07).
RISK OF DEMENTIA IN PATIENTS WITH PD
AS COMPARED WITH THAT
IN CONTROL SUBJECTS
Five hundred seventy-two control subjects were non¬
demented at their baseline visit and had at least one
follow-up visit. Eighty-seven patients became
demented during the 2-year period. Patients with PD
were significantly younger than control subjects(mean age of patients with PD, 71.1 years; mean age of
control subjects, 73.9 years), better educated (dura¬
tion of education of patients with PD, 10.7 years;
duration of education of control subjects, 9.6 years),
and more frequently men (patients with PD, 47.1%;
control subjects, 26.9%). Therefore, in addition to
group (patients with PD or control subjects), gender
and education (duration, >8 or <8 years) were
included as covariates in the model to predict incident
dementia. The Cox model was stratified by the median
age (>72 or <72 years).
When gender, education, and group membership
were included in the model, group membership (con¬
trol subjects or patients with PD) and education were sig¬
nificantly associated with the incidence of dementia. A
patient with PD was almost twice as likely to become de¬
mented than someone without PD (RR, 1.7; 95% confi¬
dence interval [CI], 1.1 to 2.7), even after adjusting for
age, education, and gender.
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Depression was not an exclusion in the group of
control subjects. The mean HDRS score in the control
subjects was 4.5, and the median HDRS score was 3.0.
Control subjects were significantly less likely to be
taking antidepressants at baseline (2.5%) than were
patients with PD (9.7%) and were also less likely to be
taking anxiolytics (3.6%), compared with 13% of the
patients with PD. In the group of control subjects, the
total HDRS score was correlated with the total EPS
(r=.15, P<.02). No correlation was seen between the
total HDRS score and the total EPS in patients with
PD. Therefore, it is unlikely that the presence of
depression in the group of patients with PD accounted
for their higher EPSs.
In the second analysis, the EPSs were examined
in patients with PD and control subjects to determine
their contribution to the risk of dementia. For this
analysis, 349 control subjects and 139 patients with
PD had EPSs recorded. Only the EPS items that were
common to the evaluations of both the patients with
PD and control subjects were included. By using the
abbreviated EPS form, patients with PD were stratified
into high and low EPSs by the median EPS, which was
14. The EPSs were classified as present or absent in
control subjects because the median score was 0, and
the mean EPS for control subjects was 1.6. One hun¬
dred eighty-one control subjects had no extrapyrami¬
dal signs and 168 had extrapyramidal signs. Only the
group of patients with PD who had high EPSs was
associated with a significant risk of incident dementia(RR, 2.3; 95% CI, 1.2 to 4.3), while neither of the
other groups (patients with PD with low EPSs or con¬
trol subjects with EPSs) were at an increased risk for
the development of dementia as compared with that
for control subjects with no extrapyramidal signs (ad¬justing for education).
Richards et al20 reported that subtle EPSs have been
shown to predict the development of dementia in el¬
derly individuals without dementia, independent of age,
education, or gender. Therefore, the analysis was re¬
peated with the group of control subjects who were strati¬
fied into a low-EPS group (no EPS or one EPS) and a high-
EPS group that represented the presence of at least two
EPSs at baseline. The patients with PD who had high EPSs
were again twice as likely as the control subjects with low
EPSs to experience dementia (RR, 2.3). Control sub¬jects with high EPSs had an RR for the development of
dementia of 1.5 (95% CI, 0.95 to 2.5) that approached
but did not reach statistical significance (P<.07), as com¬
pared with that in control subjects with low extrapyra¬
midal signs.
COMMENT
We found that having severe extrapyramidal signs was
the best predictor for the development of dementia, in¬
dependent of age in patients with PD. Age at onset of the
motor signs of PD was not a significant independent pre¬
dictor of incident dementia in this cohort, although the
stratification of age (^67 or >67 years) would not be
considered a traditional cutpoint for young- and older-
onset PD. We intentionally tried to recruit a cohort of
patients who were older than 60 years at their baseline
visit.
Although more severe depressive symptoms were
associated with an independent risk for the develop¬
ment of dementia, it is unclear from this analysis
whether depressive symptoms are a true risk factor or
an antecedent for the development of dementia since
the high HDRS scores (>10) were specific but not
sensitive indicators of DSM-III-R criteria for major
depression. Moreover, by substituting the mood item
from the HDRS, which was the most sensitive and spe¬
cific indicator of major depression, or the median
HDRS score in the proportional hazards model, de¬
pression was not an independent risk factor for
dementia, although a high EPS remained so.
To our knowledge, this is the first study to exam¬
ine the incidence of dementia in patients with PD as
compared with that in community-dwelling elderly
persons without neurological impairment. We found
that having PD increases the risk of dementia almost
twofold after adjusting for age, education, and gender.
In a similar analysis, an increased risk of dementia was
seen only in the patients with PD who had the
most severe extrapyramidal signs, and not in the
patients with PD who had lower EPSs or in control
subjects with extrapyramidal signs when control sub¬jects without extrapyramidal signs were considered as
a reference.
EXTRAPYRAMIDAL SCORE
We1 and other investigators21 have previously reported
that in patients with PD, the severity of the EPS is
associated with dementia. Dopamine deficiency might
underlie both cognitive and motor manifestations.
Dementia in patients with PD has been linked to neu¬
ronal loss in the medial substantia nigra, which
projects to the caudate nucleus and frontal association
area,22 while the classic motor manifestations of PD
are associated with a loss of dopaminergic neurons in
the lateral substantia nigra that project to the putamen
and then to the premotor areas. The relationship
between the severity of the EPS and dementia might
represent a parallel decline of these two dopaminergic
pathways. Of course, other neurotransmitter systems
may be contributing to the development of dementia.
Several single-photon emission computed tomo¬
graphic studies have shown significantly lower tempo¬
roparietal perfusion in demented compared with non¬
demented patients.2325 Also, pathological changes that
have been reported in patients with PD who had
dementia include those associated with Alzheimer's
disease and Lewy body disease.
DEPRESSION
Depression has been reported in 4% to 70% of patients
with PD, depending on the patient selection criteria, as¬
sessment techniques, and diagnostic criteria for depres¬
sion. A majority of recent studies that have used stan¬
dardized rating scales and formal criteria have reported
frequencies of 40%.26
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Using the Present State Examination, patients
with major depression at baseline were more likely to
show significant cognitive and functional decline than
were patients with minor or no depression, when they
were assessed at 1 year later, regardless of whether the
depression had resolved at follow-up.6 Widespread
pathological changes have been found in the dopamin¬
ergic ventral tegmental area in patients with PD who
had depression and cognitive impairment.27 This area
has been linked to reward and reinforcement in
animals. Disruption might cause apathy or lack of
motivation—symptoms that are often seen in depres¬
sion. A further link between depression and cognitive
impairment in patients with PD was reported by
Mayberg et al.28 When patients with PD who had de¬
pression were matched to nondepressed patients with
PD by age, disease duration, and stage of illness, posi¬
tron emission tomographic studies revealed a signifi¬
cantly lower metabolic activity in the head of the cau¬
date nucleus and in the orbital-inferior frontal cortex
in the depressed patients.28 Degeneration of the meso-
corticolimbic dopaminergic system was suggested, but
in addition, a loss of cortical outflow from this region
to the dorsal raphe might explain a secondary sero¬
toninergic deficiency. Serotonin metabolites have been
associated with depression in patients with PD,29"30
and patients with both depression and dementia have
the lowest levels of 5-hydroxyindoleacetic acid.31
Depressive symptoms may be associated with demen¬
tia because of common dopaminergic and serotoniner¬
gic deficits. Clearly, there is a possibility of an ana¬
tomical and neurochemical substrate in PD that makes
patients vulnerable to both conditions.
RISK OF PD AS COMPARED WITH THAT
IN CONTROL SUBJECTS
We found that nondemented patients with PD were al¬
most twice as likely to develop dementia than were non¬
demented control subjects from the community. This es¬
timate is probably conservative. The incidence rate of
dementia in control subjects was 80.0/1000 person-
years, which is high compared with that in other re¬
ports because control subjects were ascertained through
service professionals. We believe the incidence rate of de¬
mentia among patients with PD, ie, 112.5/1000 person-
years, is accurate.
The present study has advantages, but also limita¬
tions. We believe ascertainment of the vast majority of
cases of PD in the community was likely.32 This is the
only study in which a full neuropsychological battery
rather than a screening mental status examination was
used to determine whether DSM-ÍIÍ-R criteria for demen¬
tia were met. The use of a neuropsychological battery
rather than a screening test minimizes diagnostic error
in the determination of dementia. Functional impair¬
ment secondary to cognitive rather than motor impair¬
ment was necessary to diagnose a subject as having de¬
mentia.
Although we are confident that patients met
research criteria for PD8"10 and DSM-III-R criteria for
dementia, pathological confirmation of the cause of
the dementia is lacking. Controversy over the impor¬
tance of Lewy body disease as an explanation of
dementia in PD may have different implications for
progression. It is unclear whether extrapyramidal
signs, HDRS scores, or any other variables predict the
development of dementia in patients with Lewy body
disease.
Patients with PD were taking a variety of medica¬
tions at the time of the baseline examination.
Levodopa, dopamine agonist, and anticholinergic use
was not significantly different in those patients who
remained nondemented as compared with that in
those who became demented. Because no patient was
demented when the examinations were initially per¬
formed, it is unlikely that medications were adjusted
or discontinued for cognitive impairment, thereby
resulting in a higher EPS.
The presence of extrapyramidal signs possibly
mediated by the degeneration of dopaminergic path¬
ways predicts the development of dementia in patients
with PD. Depressive symptoms, too, may serve as a
marker of low metabolic reserves in the prefrontal cor¬
tex. Although the relative contribution of various neu¬
rotransmitter deficiencies is unknown, severity of
extrapyramidal signs and possibly depressive symp¬
toms in patients with PD may predict the development
of dementia. Patients with PD, especially those with
more severe extrapyramidal signs, have nearly twice
the risk for the development of dementia as compared
with that in control subjects.
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